Buy these 2 impressive ASX 200 shares in June 2022: experts

BlueScope is one of the ASX shares that experts really like right now.

| More on:
A white and black clock face is shown with three hands saying Time to Buy reflecting Citi's view that it's time to buy ASX 200 banks

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Experts really like these two ASX shares in June 2022
  • BlueScope Steel is benefiting from strong steel prices in the US and Australia
  • CSL is Australia’s largest healthcare business and is currently looking to acquire Vifor Pharma

We're coming into the final month of the Australian tax year. June 2022 could be a good month to invest in some of the S&P/ASX 200 Index (ASX: XJO) shares that experts have picked out as opportunities.

Different brokers have different opinions on various ASX 200 shares. However, when several brokers all think a business is a buy then it could be worth paying attention to that optimism. Or they could all simultaneously be wrong!

After all of the recent volatility of the ASX share market, the below two picks are highly recommended right now.

BlueScope Steel Limited (ASX: BSL)

BlueScope is a large steel business with operations in Australia and the US.

It's currently rated as a buy by at least five brokers, including Citi. The broker has a price target of $22.50 on the business. That implies a possible rise of the BlueScope Steel share price of more than 20% over the next year. Other brokers have even more optimistic price targets.

Citi points to strong steel prices in the US which means things are looking good for potential profit generation by North Star and the North American coated business.

The Australian steel division is also benefiting from strong steel prices and better than expected contributions from the downstream businesses. However, it has seen softer than expected domestic despatch levels, due to a range of supply chain disruptions including the flooding on the east coast, rail outages, and COVID-19 impacts.

However, the ASX 200 share expects ongoing strength in raw material prices, combined with supply chain disruptions.

It now expects underlying earnings before interest and tax (EBIT) for the second half of FY22 to be in the range of $1.375 billion and $1.475 billion, which was an upgrade from the previous range of $1.2 billion to $1.35 billion.

In early trading on Tuesday, the BlueScope Steel share price is down 2% to $18.14.

CSL Limited (ASX: CSL)

CSL is one of the largest companies on the ASX. The healthcare giant provides various products including protein-based therapies and vaccines.

It's currently rated as a buy by at least five brokers, including Citi. The broker has a price target on the business of $335, implying a potential upside of more than 20% on the current CSL share price of $274.05.

The broker points to positives that could boost the CSL share price including the acquisition of Vifor Pharma and strong demand for its products. Earlier in May, the company told investors that the regulatory approval process will take "a few more months".

Management is still confident of completing the acquisition. It's looking forward to expanding its presence in the rapidly growing nephrology market, as well as leveraging the companies' combined expertise.

Based on the current earnings estimates for CSL, Citi thinks the CSL share price is valued at 39x FY22's estimated earnings and 31x FY23's estimated earnings.

This ASX 200 share is expecting to generate net profit after tax (NPAT) in FY22 of between US$2.15 billion and $2.25 billion in constant currency terms.

Citigroup is an advertising partner of The Ascent, a Motley Fool company. Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

A man holding a cup of coffee puts his thumb up and smiles while at laptop.
Broker Notes

Guess which ASX 200 share Goldman Sachs says is a buy

The broker doesn't think Trump will spoil the party for this stock.

Read more »

A woman with strawberry blonde hair has a huge smile on her face and fist pumps the air having seen good news on her phone.
Broker Notes

Bell Potter names the best ASX 200 stocks to buy in November

These quality stocks are top picks in November according to the broker.

Read more »

Male building supervisor wearing high vis vest and hard hat stands and smiles with his arms crossed at a building site
Broker Notes

1 ASX 300 stock just upgraded by brokers (and 2 downgraded)

Here's the latest ratings changes.

Read more »

a man in a business suite throws his arms open wide above his head and raises his face with his mouth open in celebration in front of a background of an illuminated board tracking stock market movements.
Broker Notes

Bell Potter names the best ASX 200 stocks to buy in November

These quality stocks are top picks in November according to the broker.

Read more »

A man sees some good news on his phone and gives a little cheer.
Broker Notes

2 ASX 300 shares to buy now for 50% to 80% returns

These shares could have big return potential according to brokers. Let's see what they are saying.

Read more »

Broker looking at the share price.
Broker Notes

3 ASX All Ords shares just got BIG upgrades from top brokers

Leading brokers believe these ASX All Ords stocks could fly higher into 2025.

Read more »

A financial expert or broker looks worried as he checks out a graph showing market volatility.
Broker Notes

Top brokers name 3 ASX shares to buy today

Here's what brokers are recommending as buys this week.

Read more »

A young man wearing a black and white striped t-shirt looks surprised.
Broker Notes

Up 45% in 2024! Can ResMed shares keep rising?

Is this high-flying stock destined to keep soaring? Let's see what one broker is saying.

Read more »